Managing juvenile absence epilepsy in younger adults — those aged 16 and above — involves specific drug selection considerations. This protocol addresses that age group directly.
The patient is a younger adult (16 years of age or older) with juvenile absence epilepsy. This age range is clinically significant when evaluating appropriate antiepileptic drug options and tolerability.
Management centres on trialling an indicated oral antiepileptic monotherapy. Guidelines recommend that each monotherapy option be attempted in sequence before any combination approach is considered. The full list of indicated agents, their evidence grades, and the complete treatment algorithm are available in the structured protocol.